SCHEMBL379470

SCHEMBL379470

Cc1cccnc1CNc1nccc2scc(Br)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.42
FGFR1 P11362 1/20 0.42
KDR P35968 1/20 0.42
NPC1 O15118 5/20 0.36
MAPT P10636 4/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 3/20 0.36
NFKB1 P19838 3/20 0.36
NFKB2 Q00653 3/20 0.36
RELA Q04206 3/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
HSP90AA1 P07900 1/20 0.36
SLC2A1 P11166 1/20 0.36
AGTR1 P30556 1/20 0.36
OPRK1 P41145 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379504 0.83 TNF (0.47) KDRNPC1MAPTKMT2AKDM4E
SCHEMBL379503 0.78 TNF (0.50) NPC1MAPTKDM4ELMNAHTT
SCHEMBL379904 0.78 UTS2R (0.49) KDM4ELMNAHTTALDH1A1RAB9A
SCHEMBL379852 0.75 UTS2R (0.54) NPC1MAPTKMT2ALMNACYP1A2
SCHEMBL379685 0.74 SMN1; SMN2 (0.47) KDRNPC1MAPTKMT2AKDM4E
SCHEMBL31129045 0.68 CYP1A2 (0.46) NPC1MAPTKMT2ALMNATDP1
SCHEMBL2368709 0.68 MAPK1 (0.69) FGFR1MAPTKMT2AKDM4ELMNA
SCHEMBL380611 0.68 HPGD (0.43) LMNACYP1A2CYP2C19L3MBTL1
SCHEMBL379638 0.67 TUBB4A (0.44) KDRMAPTKMT2AL3MBTL1DYRK1B
SCHEMBL2082460 0.66 NOS3 (0.45) IGF1RFGFR1KDRNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 IGF1R 2959/4885FGFR1 2860/4885KDR 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.